Compare TCBK & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCBK | DMRA |
|---|---|---|
| Founded | 1975 | 2011 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 1995 | 2020 |
| Metric | TCBK | DMRA |
|---|---|---|
| Price | $51.26 | $22.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $54.60 | $43.00 |
| AVG Volume (30 Days) | 106.9K | ★ 316.7K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | ★ 6.94 | N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $53,445,000.00 | N/A |
| Revenue This Year | $12.03 | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $49.27 | ★ N/A |
| Revenue Growth | ★ 4.12 | N/A |
| 52 Week Low | $39.84 | $16.50 |
| 52 Week High | $53.18 | $28.76 |
| Indicator | TCBK | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 53.42 | 41.75 |
| Support Level | $48.57 | $18.59 |
| Resistance Level | $53.18 | $27.70 |
| Average True Range (ATR) | 1.22 | 1.99 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 58.12 | 36.16 |
TriCo Bancshares is a California corporation organized to act as a bank holding company for Tri Counties Bank. The Bank is a California-chartered bank that is engaged in the general commercial and retail banking business in California counties. The Bank provides a breadth of personal, small business, and commercial financial services, including accepting demand, savings and time deposits and making small business, commercial, real estate, and consumer loans, as well as a range of treasury management services and other customary banking services including safe deposit boxes at some branches. The company's primary source of revenue is the net interest income.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.